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Abstract 	
 
Statin drugs have been widely studied for their efficacy in secondary prevention by preventing 
the recurrence of cardiovascular disease (CVD), however their use as a primary prevention 
strategy in individuals without documented CVD, especially at low risk, is highly controversial 
among the medical community. The current research study used data from the Canadian Primary 
Care Sentinel Surveillance Network (CPCSSN); a database that houses point-of-care data from 
physician electronic medical records (EMR) from primary care practices all across Canada. It is 
a valuable resource to conduct outcomes research on diseases and conditions managed in 
primary care.  
 
This retrospective inception cohort study assessed whether statin drug use over a period of five 
years (January 1, 2009 to December 31, 2013) reduced outcomes of CVD and all-cause mortality 
in a group of primary prevention patients (i.e. patients who have never had CVD) from 
Newfoundland and Labrador (NL). The CPCSSN database was linked to both the Clinical 
Database Management System and Mortality Registry housed at the Newfoundland and 
Labrador Center for Health Information (NLCHI).   
 
The results based on univariate analysis suggested that statin drug use was associated with 
increased rates of CVD, hospitalization and coronary artery disease (CAD). However, these 
apparent harmful effects of statins in causing CVD were no longer present when other risk 
factors of CVD (sex, age, BMI, LDL-C, HDL-C, HTN, smoking status, total cholesterol, total 
triglycerides and blood pressure) were controlled for using logistic regression. Statin drugs were 
also significantly associated with decreased rates of all-cause mortality, and this beneficial effect 
persisted after controlling for CVD risk factors. Our results also demonstrated that statins were 
significantly associated with an increase in diabetes mellitus (DM) over the study period. The 
results obtained were similar when we considered compliance and used only those in the 
exposure group who had used statins for ≥ 80% of the five year follow up period.   
 
The use of statin drugs in a primary prevention situation is still controversial, and the results of 
this study provide real world data from EMR practices in NL on the effects of statins on CVD 
outcomes and death. This study concludes that at best, statins had no effect on CVD outcomes 
but decreased all-cause mortality. The results of a “real-life” assessment of the benefits of using 
statins in a primary prevention situation are not nearly as impressive as what clinical trials 
suggest. 
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Chapter 1 
Introduction 
 
HMG-CoA reductase inhibitors (Statins), the class of drugs shown to lower low-density 
lipoprotein cholesterol (LDL-C), are among the most widely used prescription drugs worldwide1. 
By lowering cholesterol, statins have demonstrated an ability to reduce the risk of cardiovascular 
disease (CVD), hospitalization, and death2. Approximately 23.6 million statin prescriptions are 
dispensed from Canadian retail drug stores each year3. 
While statins have demonstrated efficacy in secondary prevention by preventing the 
recurrence of CVD, their use as a primary prevention strategy is highly controversial among the 
medical community4. Currently, there is much debate over whether statin drugs should be 
prescribed more broadly for primary prevention or provided only to those at a very high risk of 
developing CVD in order to avoid unnecessary adverse effects and overmedicating the general 
public5.  
One of the main arguments opposing the use of statins as a primary prevention strategy is 
that these drugs do not prevent the onset of CVD enough and that statin drugs may not “achieve 
an acceptable risk-benefit ratio when treating patients who might have a very small absolute 
event reduction from statin therapy”6. A meta-analysis published in the Lancet reported that a 1 
mmol/L reduction in LDL-C in low risk individuals resulted in “an absolute reduction in major 
vascular events of about 11 per 1000 over 5 years”4. The number needed to treat (NNT) is also 
high, and studies have indicated that in order to prevent one cardiovascular event, 71 primary 
prevention patients would have to be treated with a statin for 3 to 5 years7. Patients who are 
prescribed statins run the risk of damaging their kidneys and muscles as well as developing 
diabetes mellitus (DM) type 21. When physicians prescribe a statin to otherwise healthy people, 
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they may potentially be exposing them to avoidable adverse effects of the drug. The question 
must be asked as to whether statin drugs should be prescribed to all individuals based on their 
LDL-C levels or whether statin treatment should be individualized on the basis of clinical 
judgement?5 
As a counter argument, other researchers and clinicians would argue that primary 
prevention of CVD using statins can be regarded as an efficient population based strategy6. On a 
clinical level a 1.1% absolute risk reduction in major vascular events may not appear significant, 
but when applied on a population basis we begin to understand the positive potential economic 
impact. CVD is a leading cause of morbidity and mortality in the western world, and individuals 
with CVD are among the highest users of healthcare resources8. Prescribing statins to patients for 
primary prevention is argued to be cost effective in the long run in terms of reductions in 
diagnostic procedures, hospitalizations, treatment and long-term care.  
It is important to emphasize, however, how careful physicians must be in prescribing 
medication indiscriminately for the sake of potentially saving government money. This is 
especially true if it means exposing otherwise healthy people to adverse side effects. As it stands, 
it is a precarious issue and will need strong supportive real world data for it to be considered. 
The purpose of the current research will be to explore the potential benefits of statin drugs in 
primary prevention using Newfoundland and Labrador (NL) point of care physician electronic 
medical record (EMR) data. This study will investigate whether these drugs decrease adverse 
health outcomes of CVD and all-cause mortality. Our composite CVD outcome includes the 
following conditions: coronary artery disease (CAD)/ischemic artery disease, cerebrovascular 
disease, peripheral artery disease, atherosclerosis, hospitalized due to CVD and death due to 
CVD.  
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Literature Review 
1.1 The Cost of CVD in Canada  
CVD is defined as any disease that “affects the heart, the blood vessels of the heart, and 
the veins and arteries throughout the body and within the brain”9. While Canadian rates of 
overall mortality from CVD have decreased by nearly 40% in the past decade, it remains the 
leading cause of morbidity and mortality claiming nearly 30% of all Canadian deaths10,11. 
According to the Public Health Agency of Canada more than 1.4 million Canadians are living 
with heart disease11. The toll on the economy is also great; CVD accounts for three out of the 
four most expensive health conditions. Annually, CVD accounts for over $22 billion in 
healthcare expenditure and loss of productivity9,12.  
1.2 Risk Factors of CVD 
Risk factors are described as influences (e.g. demographic, clinical, genetic, lifestyle) that 
contribute to one’s likelihood of developing CVD or that contribute to worsening of preexisting 
CVD. Examples of risk factors include hypertension (HTN), DM, obesity, smoking, excessive 
alcohol consumption, little to no physical activity, and low income13. The Heart and Stroke 
Foundation (2015) reports that 90% of Canadians have at least one risk factor for CVD9. It is 
suggested that attempting to modify risk factors could reduce the incidence and prevalence of 
CVD.  
Elevated levels of LDL-C, or ‘bad’ cholesterol as it is more commonly known, is an 
extremely important risk factor and one on which this research will focus. LDL transports 
cholesterol from the liver throughout the rest of the body and allows it to collect as plaques on 
the walls of blood vessels; a condition called atherosclerosis14. A buildup of plaque can harden 
and narrow arteries, making it more difficult for oxygen-rich blood to travel to the heart and 
other peripheral organs. As a result, this can lead to a heart attack, stroke or death15. Nearly 60% 
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of Canadian adults (ages 40-59) are living with high levels of LDL-C10. Globally, the prevalence 
of raised cholesterol among adults is estimated to be approximately 39%16. 
1.3 Global Risk Assessment Score (Framingham Risk Score) 
Individuals at risk of CVD can be categorized based on their prospective percent (%) risk 
of developing CVD within the next 10 years. This risk level in part explains why a forty-five-
year-old female who exercises daily and maintains a healthy diet is less likely to develop CVD 
compared to a hypertensive male in his late sixties who smokes. It also explains why we may 
initiate preventative treatment in someone with a high risk lifestyle and not initiate treatment in 
someone else of the same age. A limitation to most of the previous research was a failure to 
account for a participant’s level of risk of developing CVD. For example: if all of the low risk 
(<10%) patients were randomized to a study’s experimental group and all of the high risk 
patients to the control group, the study could potentially overestimate the beneficial effects of 
statins.   
As previously discussed, a multitude of risk factors often coexist and can contribute to 
CVD. The Framingham global risk assessment tool is a validated epidemiological global risk 
algorithm tool used to predict one’s risk of developing CVD over the next 10 years6,19,20. The 
Framingham risk score (FRS) takes into account a patient’s age, TC, smoking status, HDL-C, 
and systolic blood pressure (BP)20. Based on their score, patients are considered as low risk 
(<10%), intermediate risk (10-19%), or high risk (≥20%). This tool is clinically useful as a risk 
estimation system as it is “methodologically robust and easy to use, addresses clinically relevant 
risk factors, and results in measurable health gain to a population”21. Additionally, the 
Framingham tool has been studied for its external validity and its ability to generalize as the tool 
is “derived from a study population with sufficient sample size that is representative of the 
population to which the function is to be applied”21. 
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The Framingham study has played a large role in the detection and treatment of heart 
disease by enabling researchers to identify some of the lifestyle and risk factors associated with 
CVD. This risk information can subsequently be used as a tool when prescribing risk-reducing 
medications such as statins. In the United States, mortalities associated with CVD have 
decreased since 1990, a trend largely attributable to using the Global risk assessment as part of a 
strategy to manage CVD19.  
1.4 Current Guidelines for Managing Cholesterol Levels 
Current cholesterol targets published by Statistics Canada (2013) and the Mayo Clinic 
suggest that normal LDL-C levels for both males and females, ages 20-79, should be below 
3.5mmol/L, high-density lipoprotein cholesterol (HDL-C) levels should be above 1.0mmol/L 
(males) and 1.3mmol/L (females), total cholesterol (TC) for both males and females should be 
below 5.2mmol/L, and total triglyceride levels (TT) lower than 1.710,17. 
The most current guidelines at the time of this study* for managing dyslipidemia in 
Canada were published by the Canadian Cardiovascular Society in 201218. Cholesterol screening 
is recommended in men >40 and postmenopausal women >50, or at any age in those with the 
following risk factors: “smoker, DM, arterial HTN, family history of premature CVD, family 
history of hyperlipidemia, erectile dysfunction, chronic kidney disease (CKD), inflammatory 
diseases, HIV infection, chronic obstructive pulmonary disease (COPD), clinical evidence of 
atherosclerosis or abdominal aneurysm, clinical manifestation of hyperlipidemia, or body mass 
index (BMI) >27”18.   
																																																								*	While we appreciate that the Canadian College of Family Physicians published more recent guidelines for the 
management of dyslipidemia in 2015, this study used the guidelines consistent with the timeline of the study. Note 
that both guidelines are very similar in terms of management principles.	
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The 2012 guidelines suggest that the FRS be used to estimate a patient’s 10-year risk of 
developing CVD, in addition to a full cholesterol screen and kidney function tests. Table 1 
presents the study’s recommendations for lipid targets and treatment. 
Table 1 Canadian Cardiovascular Society guidelines for the management of lipids by statin 
therapy (2012). Summary of treatment targets based on Framingham Risk. Source: 
http://www.onlinecjc.ca/article/S0828-282X(12)01510-3/pdf 
Risk Level Initiate therapy if Primary LCL-C 
target 
Alternative targets 
High risk:  
FRS ≥ 20% 
Or in patients with: 
DM, CKD, high risk 
HTN, atherosclerosis 
or an aortic aneurysm 
Consider treatment 
in all  
≤2 mmol/L or ≥ 50% 
reduction in LDL-C 
from baseline  
Apo B ≤ 0.8 g/L or non 
HDL-C ≤ 2.6 mmol/L  
 
Intermediate risk:  
FRS 10-19%  
LDL-C ≥3.5mmol/L  
For LDL-C <3.5 
mmol/L consider if: 
Apo B ≥1.2g/L or 
non-HDL-C ≥4.3 
mmol/L 
≤2 mmol/L or ≥ 50% 
reduction in LDL-C 
from baseline 
Apo B ≤ 0.8 g/L or non 
HDL-C ≤ 2.6 mmol/L  
 
Low risk:  
FRS <10%  
LDL-C ≥5mmol/L or 
familial 
hypercholesterolemia 
≥ 50% reduction in 
LDL-C  
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1.5 Statin Drugs  
Several types of statins exist and are sold under a variety of brand names: Lipitor 
(atorvastatin), Zocor (simvastatin) and Crestor (rosuvastatin) are examples of three commonly 
used high-potency statins. This research employs the umbrella term ‘statin’ to refer to the 3 
brands of statins previously listed. Statin drugs are among the top three cardiovascular 
medications dispensed in Canada, along with angiotensin converting enzyme inhibitors (ACE-I) 
and diuretics22. Approximately 23.6 million statins are prescribed each year in Canada3.  
Statins lower LDL-C by inhibiting HMG-CoA reductase, the rate-limiting enzymatic step 
in cholesterol synthesis, and thus act to decrease the liver’s ability to synthesize cholesterol23. 
Statins also have non lipid related effects; they possess “anti-inflammatory properties, inhibit 
vascular smooth muscle cell proliferation as well as platelet function, and improve vascular 
endothelial function”23. While studies are ambiguous, it has also been suggested that statins 
slightly increase the levels of HDL-C, or ‘good cholesterol’24. 
1.5.1 Side Effects of Statin Drugs 
As with most pharmaceuticals, statin drugs have the potential to cause adverse effects.  
The most commonly reported adverse effects in clinical settings involve the musculature system 
(e.g. myalgia and myopathy), as well as symptoms of fatigue and weakness25. The adverse 
effects related to muscles range from mild to severe, “and is believed to occur in up to 10-15% of 
exposed subjects in real world practice”26. A number of randomized control trials (RCT) with 
large sample sizes have “not shown significant differences in the number of subjects reporting 
muscle symptoms between statin and placebo-allocated groups”27. Batteries of trials have 
assessed the safety of statins and have reported that by and large they are a “safe and tolerable 
medicine having considerable risk/benefit ratio with the display of only mild and transient 
adverse effects”25. The more severe side effects include rhabdomyolysis – severe muscle damage 
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leading to elevated levels of creatinine kinase (CK)28. This side effect is rare (approximately 
5/100000 patient-years)25,28, and to date neither RCT data nor meta-analyses support a significant 
increase in rhabdomyolysis following statin use28. “Amongst 35 trials including 74,102 subjects 
over a mean of 17 months follow up reported that statin therapy did not increase the overall risk 
of rhabdomyolysis compared with placebo29.  
Other very rare side effects commonly linked to statins are: hemorrhagic stroke, cognitive 
impairments, gastrointestinal tract impairments (e.g. nausea, abdominal pain, diarrhea), cataracts 
and ocular hemorrhaging, erectile dysfunction, and decreased blood clotting22. While research 
has remained inconclusive, pregnant women are advised not to take statins as they have 
demonstrated the potential to cause congenital abnormalities30.  
There is currently much debate as to whether statin drugs increase the risk of cancer and 
to date there is no evidence supporting this4. A report published by the Statin Intolerance Panel 
(2014) suggested that “no effect of statin treatment on cancer incidence or mortality was evident 
in a meta-analysis of individual data from 175,000 patients in 27 randomized clinical trials of 
statins”27. Additionally, meta-analyses whose follow up period was greater than 6 years found no 
increase in the incidence of cancer with statin therapy29. 
Another reported side effect of statin use is the incidence of new-onset DM type 2. For 
this reason the “US Food and Drug Administration in 2012 added a statement to the labels of 
statin medications indicating that increases in glycated hemoglobin (HbA1C) and fasting glucose 
levels have been reported with statin use”31. This raised concerns among physicians in respect to 
prescribing statins to patients with pre-existing DM and those with DM risk factors31. Statin 
drugs are thought to cause hyperglycemia by either disrupting the voltage gated calcium 
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channels in pancreatic beta cells (decreasing insulin production), or by decreasing the number of 
GLUT4 (glucose transporters) on the intracellular membrane of muscle cells31. 
A report from the Diabetes Subpanel of the National Lipid Association Expert Panel on 
Statin Safety (2014) reported that despite the modest, but “clinically significant increase in the 
odds for new-onset DM (∼10% compared with placebo or usual care)31, no changes to clinical 
practice are recommended other than the measurement of HbA1C or fasting glucose in those 
deemed to be at elevated DM risk”31. Another study published by Shah et al., (2016) reported 
that “diabetes mellitus was diagnosed in 27% more patients receiving rosuvastatin therapy 
compared with patients receiving placebo”32.  
These results are replicated in other large studies published after 2014, including reviews by 
Beckett et al., (2015), Bernardi et al., (2015) and Agouridis et al., (2015). Their studies offer 
similar conclusions to the Statin Diabetes Task Force report; that statin drugs show a statistically 
significant increase in the risk of new-onset DM type 2, but this risk is not clinically 
significant33. Bernardi et al., (2015) suggest that risk factors of “age, potency of statin therapy, 
presence of metabolic syndrome, impaired fasting blood glucose, obesity and previously altered 
glycated hemoglobin levels” contribute to the likelihood of developing DM from statins34. 
Agouridis et al., (2015) report that “lipophilic statins are more diabetogenic than the hydrophilic 
ones”35. Despite all of this data, it is still believed among the medical community that the well-
established benefits of statin therapy in reducing cardiovascular events outweigh the risk of 
developing DM35. 
1.5.2 Medication Compliance  
It is important to be conscious of the fact that the low reporting of side effects in many RCTs 
is likely attributed to the pretrial run-in phase. This preliminary phase screens participants for 
their ability to tolerate statins and their side effects in addition to their compliance in taking the 
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medication. Additionally, these trials often “drop patients who have had a previous history of 
statin intolerance”27. Patients who fail to meet certain thresholds are often excluded from the 
study, resulting in a potential overestimation of the beneficial effects of statin drugs. 
In a real world setting, where medication adherence is not as tightly controlled, many 
patients do not take their medication as prescribed by their physician due to adverse events even 
though patients are aware of the medications proven benefits. Bosomworth (2011) suggests, 
“fewer than 50% of patients take 80% or more of their prescribed statin dosages”6.  Statin 
adherence rates after 5 years are estimated to be a low as 25%, with nearly one-third of patients 
discontinuing therapy within the first year36. Shalev et al., (2012) studied the role of statin use for 
primary prevention using a retrospective cohort study and stratified the cohorts based on statin 
persistency (proportion of days covered (PDC)). The authors argue in favor of this type of study 
design by suggesting that the effectiveness of statins when studied using an RCT is often 
overestimated due to “premature truncation, selective inclusion of high-risk patients, high level 
of patient care, and titration management which may affect their generalizability to everyday 
practice”37. A retrospective cohort study can “tackle these limitations and quantify the true effect 
size of statins in “real-world” community practice with higher external validity”37. In that study, 
patients were classified as: <20%, 21% to 39%, 40% to 59%, 60% to 79%, ≥80% compliant with 
their statin medication. Results indicated a significant decrease in CVD events with each 
increasing PDC category, and found persistent statin users (≥80%) to have a 22.72% (95% CI: 
22.3 to 23.1) lower probably of CVD within the next 10 years compared to non-persistent users 
(<20%)37. For those patients who chose to discontinue statin treatment due to adverse events, 
there was no randomized, clinical trial evidence that musculature, hepatic, or cognitive effects 
were irreversible27,36.  
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1.5.3 Primary vs. Secondary Prevention: Previous Literature on Statin Use  
The act of preventing or reducing the progression of a disease can be broken into a series 
of prevention strategies. In primary prevention, the goal is to prevent a disease from occurring, 
and is accomplished by risk reduction. Primary prevention generally targets specific modifiable 
risk factors for a given disease38. In contrast, secondary prevention is an ‘after the fact’ measure 
that attempts to control the progression of a disease. If a disease is discovered in its early stages, 
secondary prevention can be used to impede more serious symptoms38.  
While the use of statin drugs for secondary prevention has proved efficacious, their use as 
a primary prevention strategy is highly debated among both the medical and research 
community, and to date research has been relatively ambiguous. As previously discussed, most 
research has grouped all primary prevention patients together as a whole without accounting for 
their level of risk of CVD, and “data has clearly supported the use of statins for high-risk 
individuals where the benefits have outweighed the risks”5. However, due consideration is 
needed “when extrapolating the potential benefits of statins on mortality to lower-risk primary 
prevention populations”39. Should statins be prescribed for primary prevention, regardless of risk 
level, or in doing so are physicians running the risk of overmedicating the general public? As it 
stands, physicians tend to individualize statin prescriptions on the basis of clinical judgement5.   
The WOSCOPS (West of Scotland Coronary Prevention Study) was one of the first 
RCTs to investigate statin use (pravastatin) for primary prevention. The study investigated 
whether statins reduced the “combined incidence of nonfatal myocardial infarction (MI) and 
death from CAD”	 in men with hypercholesterolemia (LDL >4mmol/L) and no prior CVD40.  
Following a five year follow up, the occurrence of the primary endpoint of nonfatal MI or 
death from CAD for the statin group compared to the control group was 5.5% vs. 7.9% (RR 
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0.69; 95% CI 0.57-0.83; P<0.001). The Statin group demonstrated a significant risk reduction in 
the primary outcome of 31% (95% CI from 17 to 43% P<0.001). The absolute difference in the 
risk of CVD after 5 years was 2.4%. It is estimated that treating 1000 men (with elevated plasma 
cholesterol and no previous CVD) for five years with pravastatin would result in “20 fewer 
nonfatal MI, 7 fewer deaths from CVD, and 2 fewer deaths from other causes than would be 
expected in the absence of treatment”40. Additionally, the WOSCOPS trial did not find any 
significant differences in adverse effects between the experimental and control group. In the 
statin group 20 subjects had myalgia and 97 had muscle aches, compared to 19 and 102 in the 
control group40. 
Brugts and colleagues (2009) performed a meta-analysis and investigated whether statins 
used in primary prevention reduced all-cause mortality and major coronary and cerebrovascular 
events in individuals with cardiovascular risk factors but no established CVD. In addition, they 
wished to examine whether these effects were similar in understudied subgroups such as women, 
older adults (>65 years), and in people with DM. The meta-analysis of 70,388 participants 
revealed that statins “significantly reduced the risk of all-cause mortality, major coronary events, 
and major cerebrovascular events”24. Total cholesterol levels were reduced by 17.1%, LDL-C by 
25.6%, and TT by 9.3%; results comparable to secondary prevention studies. Compared to 
controls, patients receiving statin therapy demonstrated a 12% relative risk reduction in all-cause 
mortality, a 30% relative risk reduction in major coronary events, and a 19% relative risk 
reduction in major cerebrovascular events24. In addition, the studies found no significant 
association between statin use and risk of cancer (OR 0.97, 95% CI 0.89 to 1.05)24.  
Brugts and colleagues (2009) concluded that statins demonstrated positive outcomes 
including improved survival “across a broad range of patients at different risk levels, and showed 
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that there was no significant difference in treatment benefit across a range of clinically defined 
groups such as men and women, elderly, and those with diabetes”24. 
The JUPITER trial (Justification for the use of statins in primary prevention: an 
intervention evaluating Rosuvastatin)41 was one of the most recent and controversial RCTs that 
assessed statin use for primary prevention in a low risk population. This study randomized 
approximately 17,000 patients from 1351 sites in 26 countries all of whom had LDL-C levels of 
<130mg/dL (<3.36 mmol/L) but were at risk of CVD due to elevated levels of high sensitivity C 
reactive protein (hsCRP) ≥2 mg/L. Relative risk reductions in specific vascular events were 
reported for the statin group compared to the control group: 54% reduction in MI (P=0.002), a 
48% reduction in stroke (P=0.002), a 46% reduction in the need for arterial revascularization 
(P<0.001), and a 20% reduction in all-cause mortality (P=0.02)”41,42.   
For healthy men >50 years and women >60 years the NNT values for 2, 3, 4 and 5 years 
were 95, 49, 31 and 25 respectively for the primary endpoint of CVD. The authors noted that 
these NNT values “compare favorably to several other therapies widely considered to be 
effective in the primary prevention of CVD”42. Both the intervention and placebo group were 
similar in the number of reported serious adverse effects: 1352 and 1377, respectively (P=0.60). 
In addition, those allocated to receive a statin demonstrated a significant reduction in cancer 
mortality compared to placebo (35 verses 58, P=0.02).  
        A study conducted by the Cholesterol Treatment Trialists' (CTT) Collaborators used the 
global risk assessment tool to categorize a patient’s risk of CVD into either low, intermediate or 
high and assessed whether the side effects of statin drugs outweighed the benefits of CVD 
reduction. A meta-analysis of 27 studies grouped patients based on their “5-year major vascular 
event risk on control therapy (<5%, ≥5% to <10%, ≥10% to <20%, ≥20% to <30%, ≥30%); in 
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each, the rate ratio per 1.0 mmol/L of LDL-C reduction was estimated”4. The results of this 
analysis demonstrated that statins significantly reduced the risk of major vascular events and all-
cause mortality “irrespective of age, sex, baseline LDL-C or previous vascular disease”4. 
Interestingly, the proportional reduction in vascular events was similar across all risk groups and 
was “at least as big in the two lowest risk categories as in the higher risk categories”4.    
1.5.4 Summary of Aforementioned Research   
The research previously discussed suggests that statin drugs, when used in primary 
prevention, significantly decreased outcomes of CVD and death in adults (45-79 years) 
compared to adults who were not taking statins. Among the studies, it was found that the statin 
groups demonstrated a significant risk reduction in the primary outcome of CVD anywhere 
between 31 and 54%, and all-cause mortality by 12-20%24,40-42. The JUPITER trial reported that 
the NNT for women > age 60 and men > age 50 for 2,3,4 and 5 years was 95, 49, 31 and 25 
respectively42. In addition, studies have demonstrated no significant difference in adverse effects 
between intervention and control group, other than DM type 2.   
While it is possible that the results from these RCTs may be an overestimation of the 
beneficial effects of statins for reasons previously discussed, the results presented by Shalev et 
al., (2012) from their retrospective cohort study addressed some of the limitation of RCTs37. 
Their study revealed a similar relative risk reduction of CVD of 27.7% for the intervention 
group, which suggested that the ability of statins to reduce CVD is significant and does apply in 
a real world setting. Additionally, previous research has suggested that statins have demonstrated 
a reduction in CVD for different types of participants regardless of their risk factor (e.g. elevated 
hsCRP levels, hypercholesterolemia, men, women, DM24).  
		 15	
1.5.5 Treatment with Statins for Longer than 10 Years 
Another aspect to consider when using statins is the duration of treatment required to 
decrease the occurrence of CVD and the time required for adverse effects to develop. Studies 
have shown that differences in clinical outcomes have been observed anywhere from 4 to 30 
months36, but despite the many studies that have been published on statins there is “very little 
randomized, controlled clinical trial evidence of statin therapy beyond 5 years”36. In addition, 
many studies are terminated early due to sufficient number of primary end points that have been 
documented36. Stopping a trial early may exaggerate positive results, produce false positives, and 
does not allow sufficient time to detect adverse effects of a drug, such as cancer.  
A study published by Soverow and Watson (2000) assessed the long-term effects of statin 
use in both primary and secondary prevention studies. The study concluded that treatment “with 
a statin for 10 years was superior to treatment for only 5 years”36. According to the results of 
their study, the authors speculated that extending statin therapy beyond 10 years would be 
expected to “(1) delay atheroma progression, (2) suppress associated vascular risk factors and (3) 
provide an overall mortality benefit and reduction in cardiovascular events”36.  
The WOSCOPS trial was a primary prevention RCT using pravastatin that demonstrated 
a 1% absolute risk reduction in all-cause mortality for the exposed group after a median follow 
up period of 4.9 years. Adding an additional 10 years of post-trial follow up revealed “a 
significant, sustained 2% (P=0.03) absolute risk reduction in all-cause mortality over the entire 
follow up period in the pravastatin group compared to the placebo group”36,43. This reduction in 
mortality was evident despite the 50% absolute drop in adherence rate among participants. The 
fifteen year follow up period also revealed that rates for nonfatal MI and coronary heart disease 
were 15.5% (placebo group) vs. 11.8% (statin group)5,43. Over the long term, “statin use resulted 
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in the stabilization of plaques, allowing for long term benefit even after users stopped taking the 
drugs”5.  
1.5.6 Economic Impact of Statin Use for Primary Prevention  
Studies by Gotto et al., (2000) have identified the economic benefits of statin use for 
primary prevention in terms of a reduction in healthcare resource utilization and cost. The study 
reported that statin treatment reduced the number of cardiovascular hospitalizations by 29%, and 
the frequency of cardiovascular hospitalizations, therapeutics and diagnostic procedures by 28%, 
32% and 23% respectively. The offset in direct cardiovascular medical costs between the statin 
and placebo group was $524 per patient, a 27% reduction “over the mean study duration of 5.2 
years”8. In their research, it was estimated that the cost of statin treatment per patient was 
$4,6548. 
Robinson (2014) explored the social and economic impact of the Adult Treatment Panel 
(ATP) III updated guidelines using data from the National Health and Nutrition Examination 
Survey. Their research indicates “the modest observed reduction in LDL-C of ~0.56mmol/L in 
statin users likely prevented 40,020 deaths, 61,074 hospitalizations for acute MI ($4.4 billion 
costs avoided), and 22,272 hospitalizations for stroke ($440 million costs avoided)44. A saving of 
$34,926 per statin user was seen after 10 years of statin use, “or a benefit-to-cost ratio of 4:1”44. 
The paper also estimates potential savings of $2.5 billion for acute MI hospitalizations, and $260 
million for stroke hospitalizations, had statins been used by all adults who were eligible 
according to the ATP III guidelines44.  
It is clear that efforts to prevent CVD are needed in order to limit the growing economic 
and social burden. “The American Heart Association estimates that by 2030, 40% of the US 
population is projected to have some form of CVD or HTN, and total medical costs of CVD are 
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expected to triple from $273 to $818 billion”14,44. The widespread availability of statins in 
addition to the low-cost of generic brands makes it a cost effective prevention strategy for CVD. 
“These data suggest that statins are more cost effective than aspirin or antihypertensive 
medication in reducing CVD mortality and morbidity in primary prevention”5.  
1.6 CPCSSN Database and Data Linkage 
Nearly 85% of people in Canada have a family physician, and over 70% visit their 
physician at least once a year45. The Canadian Primary Care Sentinel Surveillance Network 
(CPCSSN) is the first national health database that draws its data from the EMRs of family 
physicians. During the timeframe of the study (January 1st 2009 to 2013), CPCSSN included 10 
research networks across Canada. There were 750 physicians who contributed de-identified data 
on over one million patients46. The network has developed specific algorithms for identifying 
various chronic diseases: COPD, depression, DM, HTN, osteoarthritis, as well as neurological 
conditions dementia, epilepsy and Parkinson’s disease46, 47 . 
This research will link patient information from the Newfoundland and Labrador 
CPCSSN (NL-CPCSSN) database with databases held by the NL’s Centre for Health 
Information (NLCHI) in an attempt to explore the relationship between statin use and outcomes 
of CVD and all-cause mortality in the province of NL. All information is de-identified in order to 
preserve anonymity of the patients. The NL-CPCSSN database has information from 50 
physicians (approximately 10% of all NL family physicians) and over 44,000 patients.  
Prior to the development of the CPCSSN database, information available on chronic 
diseases in Canada was derived from sources such as hospital discharge summaries, billing data 
and population health surveys48. However, these datasets were limited by their “inability to 
capture data on conditions that did not lead to hospitalizations”48,49. Additionally, they were 
often created for financial management rather than research purposes, and were unreliable when 
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dealing with self-reporting of subjects48,49.  The CPCSSN database attempted to mitigate the 
aforementioned limitations by using a primary care database, which was beneficial in that it 
“provided a prospective and systematic collection of clinically verified data that could be 
comprehensive for studying a variety of important outcomes”48,50. The use of CPCSSN data for 
this research allowed us to answer our question with real-world, point of care physician EMR 
data from NL.  															
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Chapter 2 
Research Objective and Questions 
 
2.1 Objective   
To investigate whether statin drug therapy decreases the occurrence of CVD† and all-cause 
mortality in primary prevention patients ages 50-70. 
2.2 Primary Question 
Do patients, ages 50 to 70 who are prescribed statins (“exposed”) for primary prevention have 
reduced outcomes of CVD and all-cause mortality compared to patients who are not prescribed 
statins (“not exposed”)? The primary question stated in PICO format is: 
P: People who are between 50 and 70 years of age as of December 31, 2008 and have no 
history of CVD 
 
I: On a statin drug for primary prevention on December 31, 2008 
 
C: Not on a statin drug on December 31, 2008 
 
O: Develop CVD or die between January 1, 2009 and December 31, 2013  	
2.3 Secondary Questions  
i) Does statin drug use predict secondary outcomes of coronary artery disease/ischemic 
heart disease, cerebrovascular disease, peripheral vascular disease, hospitalization 
(any reason), hospitalization due to CVD, or death due to CVD?  
ii) To what degree does statin exposure predict the primary outcomes of CVD and all-
cause mortality when significant CVD risk factors are controlled for?  
																																																								
† The composite outcome of CVD includes: coronary artery disease/ischemic artery disease, cerebrovascular disease, 
peripheral artery disease, atherosclerosis, hospitalized due to CVD, death due to CVD 
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iii) To what degree does statin exposure predict the primary outcomes of CVD and all-
cause mortality when significant CVD risk factors are controlled for in a population 
of medication compliant (≥80%) patients?  
iv) Is there an increase incidence of diabetes mellitus in people using statins?‡ 
2.4 Hypothesis  
2.4.1 Null Hypothesis (H0) 	 There will be no statistically significant difference in the incidence of CVD or all-cause 
mortality between the exposed and non-exposed groups. It will remain a non-significant 
difference even when risk factors for CVD (e.g. age, sex, diagnosis of HTN, smoker, LDL-C, 
HDL-C, BMI, sBP and dBP) are controlled for.  
 There will be no significant difference in the incidence of DM in the exposed group vs. 
non-exposed group.  
2.4.2 Alternative Hypothesis (Ha) 
	 In accordance with previous literature, we anticipate that the data will show a decrease in 
the rates of CVD and all-cause mortality for patients in the statin exposed group. Using the study 
conducted by Shalev et al., (2012) as a guideline, we hypothesize that the exposed group would 
demonstrate a 25-30% relative risk reduction in CVD compared to the non-exposed group. This 
reduction in the incidence of CVD will persist even when controlling for significant risk factors 
of CVD.   
																																																								
‡ The CPCSSN database cannot identify between DM Type 1 and Type 2. In this age group we assume that an 
overwhelming majority of new onset cases are Type 2.     
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We do expect a statistically significant increase in the incidence of DM in the exposed 
group vs. non-exposed group based on studies published by the Diabetes Task Force31 and Shah 
et al., (2016).  
2.5 Significance of Study and Clinical Implications  
While statins have proven efficacious for secondary prevention, their use among primary 
prevention patients in a real world setting warrants further research. Unlike many RCTs that do 
an initial pretrial run-in phase and only randomize compliant patients, the current research will 
provide data from a real-world source on the effects of statins in decreasing adverse health 
outcomes. In addition to any clinical implications, this research may provide evidence for an 
economically viable way to reduce healthcare expenditure on CVD and CVD related procedures.  
As previously discussed, CVD currently accounts for over $22 billion in healthcare expenditure 
and loss of productivity12. Prescribing statins for primary prevention could potentially decrease 
healthcare resource utilization in terms of emergency room visits, hospitalizations and diagnostic 
services. 
The current study will expand on previous literature in the following ways: (i) the study 
followed patients retrospectively for a full five year follow up period, eliminating the potential 
for early termination and (ii) this study is the first ever linkage study using CPCSSN EMR data.    
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Chapter 3 
Methods 
3.1 Study Design 
This was a retrospective inception cohort study of primary prevention patients aged 50 to 
70 years. The purpose was to determine whether the use of statin drugs decreased the 
development of CVD or all-cause mortality over a five-year period (January 1, 2009 to 
December 31, 2013) compared to a cohort of patients who were not using statin drugs. There was 
no recruitment period for this study as the baseline data was collected at the study’s start date 
(zero time): January 1, 2009. There was a clearance period of two years to ensure that outcomes 
were new cases.     
We analyzed secondary data from the NL-CPCSSN database, which was linked to both 
the NL hospitalization database -- Clinical Database Management System (CDMS) -- and the 
NLCHI mortality system to establish the cohorts and assess outcomes.  
3.2 Participants: Establishing the Study Cohort 
The study population consisted of people in the NL-CPCSSN database who on December 
31, 2008 were between the ages of 50 and 70 years and had no previous history of CVD during 
the two-year clearance period. These individuals would be in a primary prevention situation. The 
exposure cohort consisted of individuals meeting the age criteria who were prescribed a statin as 
of December 31, 2008. The non-exposed cohort consisted of individuals who were not 
prescribed a statin drug as of December 31, 2008 or 6 months prior. The total number of patient 
records used in this study was 9,134. Although we have no way of knowing whether patients 
who were prescribed a statin were actually filling/using their medication, our study is based on 
the assumption that the exposed group are those who were on a statin drug at baseline because 
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they had received a prescription prior to the baseline date and there was no indication it had been 
stopped by the physician.  
3.3 Data Sources   
3.3.1 Description of Dataset (CPCSSN) 
Data from the CPCSSN database was accessible through NLCHI and all data was de-
identified. The dataset used for this research project consisted of only NL data. CPCSSN uses a 
variety of algorithms in order to identify patients with chronic conditions. These diagnostic 
algorithms use information from billing data, laboratory test results, medications, health 
conditions/problem list and encounter diagnostics in order to create a disease definition and 
identify a diagnosis.  
Validation studies on CPCSSN data have been conducted at both the Kingston Network 
(Queen’s University, Ontario) and the APBRN network (Memorial University, NL), “in order to 
assess the validity of EMR-based diagnostic algorithms for the five chronic conditions in the 
CPCSSN database”48. The specificity and sensitivity for all five chronic conditions (DM, HTN, 
osteoarthritis, COPD and depression) were very high, suggesting that “the diagnostic algorithms 
yield few false-positive cases…and the majority of true cases are being identified correctly by 
the CPCSSN algorithms”48. 
Because our study was observational and relied on health data previously recorded by 
physicians, the only potential risk was identification of an individual. CPCSSN and NLCHI have 
in place strong de-identification processes to reduce that risk to a minimum. All data that was 
extracted was de-identified.  
The CPCSSN network takes great precautions in order to preserve patient privacy. Each 
CPCSSN network employee is required to pass a privacy seminar and sign an oath of 
confidentiality, no identifying information e.g. names, addresses, or telephone numbers were 
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extracted from the EMRs and all computer files pertaining to the study were password protected. 
CPCSSN has its own Privacy and Ethics Standing Committee that deals with issues of data 
collection, patient confidentiality, privacy and ethics approval, and this committee carries out 
regular privacy assessments and audits at regional networks.  
3.3.2 Description of Dataset: (CDMS) 
Hospitalization data was provided by the CDMS and was accessible through NLCHI. All 
data was de-identified. The CDMS contained information on patient demographics, as well as 
clinical and administrative hospital data when patients were discharged from inpatient and 
surgical care services.  
3.3.3 Description of Dataset: (NLCHI Mortality System)  
Mortality data was provided by the NLCHI Mortality System database and was 
accessible through NLCHI. All data was de-identified. The database contained demographic, 
administrative and clinical data from patients who died in the province of NL. 
3.3.4 Description of Variables  
Table 2 provides a description of each variable as well as the database it was extracted from. 
Demographic data was collected at baseline (December 31, 2008) and outcome data was 
collected at the end of follow up (Dec 31, 2013).  
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Table 2 Source and Description of Study Variables  
Type of 
Variable 
Variable Description of Variable ICD94 or ATC5 code Database 
Exposure Statin  Statin prescribed=patients who are listed in the 
CPCSSN database as being on a statin drug at baseline 
(Dec 31, 2008) 
 
Statin not prescribed=patients who have not used a 
statin within 6 months of baseline  
 
ATC code starting with 
C10AA and/or drug name 
ending in “statin” 
 
 
CPCSSN  
Outcome CVD Coronary artery disease/ischemic heart 
disease/angina 
• Acute myocardial infarction 
• Other acute and subacute forms of ischemic 
heart disease 
• Old myocardial infarction 
• Angina pectoris 
• Other forms of chronic ischemic heart disease 
 
Cerebrovascular Disease  
• Occlusion of cerebral arteries 
• Transient cerebral ischemia 
• Acute but ill-defined cerebrovascular disease  
• Other and ill-defined cerebrovascular disease 
• Late effects of cerebrovascular disease 
 
Peripheral Vascular Disease  
 
Atherosclerosis 
 
 
ICD9 code (410)  
ICD9 code (411) 
 
ICD9 code (412)  
ICD9 code (413) 
ICD9 code (414)  
 
 
ICD9 code (434) 
ICD9 code (435) 
ICD9 code (436)  
ICD9 code (437)  
ICD9 code (438)  
 
ICD9 code (443)  
 
ICD9 code (440) 
 
 
 
 
 
 
 
 
CPCSSN  
 
*Data is 
extracted from 
health 
conditions and 
billing or 
encounter 
CPCSSN EMR 
tables 
 
																																																								4	International Classification of Diseases, Version 9  
5 Anatomical Therapeutic Chemical (ATC) Classification System	
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Outcome Composite 
outcome of 
CVD: created 
for the study  
Coronary artery disease/ischemic artery disease, 
cerebrovascular disease, peripheral artery disease, 
atherosclerosis, hospitalized due to CVD, death due to 
CVD  
 CPCSSN, 
CDMS and 
NLCHI 
Mortality 
System 
Outcome Diabetes 
 
 
CPCSSN Case Definition (National data: 100% 
sensitivity, 99% specificity, NL only data: 95.6% 
sensitivity, 97.1 specificity)48 
 
Billing Data: ICD9 code 250.x, Medications: insulin, 
glyburide, metformin, Laboratory tests results: 
HbA1C >7%, fasting blood sugar >7 mmol/L, 
Problem list: diabetes/NIDDM/DM, Procedures: 
revascularization procedures, coronary artery disease 
investigation, Referrals: ophthalmology, nephrology, 
neurology, endocrinology, diabetes education, dietician  
 
*Note: These were incident cases of diabetes with a 
clearance period of two years.  
 
 
 
 
 
 
 
ICD9 Code (250.x) 
 
 
 
 
 
 
 
CPCSSN  
Outcome Hospitalization  Admitted to hospital for any reason  
 
Admitted to hospital for CVD 
  
CDMS  
Outcome Death  Did death occur between January 1, 2009 and Dec 31, 
2013.  
 
Number of months after enrolment patient died  
 
Was the cause of death due to CVD?  
  
 
NLCHI 
Mortality 
System  
Covariate  Age   CPCSSN  
Covariate  Sex   CPCSSN  
Covariate  Hypertension  CPCSSN Case Definition (National data: 83% 
sensitivity, 98% specificity, NL only data: 84.9% 
sensitivity, 93.5% specificity)48,49 
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Billing Data: ICD9 code 401, Medication: ACE-
I/ACB, diuretics, beta blockers, calcium channel 
blockers, alpha blockers, Problem list: hypertension, 
Procedures: angioplasty, coronary artery stent, 
Referrals: cardiology and nephrology44  
ICD9 code (401)  CPCSSN  
Covariate Smoking 
Status  
Current Smoker, Past Smoker or Non Smoker at 
baseline and follow up 
 CPCSSN  
Covariate Lipid Profile Total Cholesterol 
LDL-C   
HDL-C 
TC/HDL ratio  
Total Triglycerides 
 
Most recent measure prior to baseline (Dec 31, 2008) 
and follow up (Dec 31, 2013)  
 
 
 
 
 
 
 
 
CPCSSN  
Covariate Blood Pressure Systolic 
Diastolic  
 
Most recent measure prior to baseline (Dec 31, 2008) 
and follow up (Dec 31, 2013) 
  
 
CPCSSN  
Covariate  Medication 
Compliance 
Calculated from a patient’s prescription start and stop 
date. Medication compliance is assumed if the exposed 
group were on a statin at baseline and had been 
prescribed the statin for 80% or more of the time (1460 
days) during the five year follow up period.  
*We are assuming that those prescribed statins are in 
fact taking their medication as directed.  
 CPCSSN 
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3.4 Sample Size Calculation  
Sample size was calculated such that if a 15% difference in outcomes was seen between the two 
cohorts it would be statistically significant. Using an alpha of 0.05 and a power of 90%, a sample size 
of 244 people was required in each of the two cohorts. This 15% difference was relevant for 
development of CVD, however detecting a smaller difference in death rates (10%) was important. 
Using an alpha of 0.5 and a power of 80% a sample size of 411 in each group was required in order to 
detect a 10% difference in death rates. However, in order to allow for subgroup analysis, we requested 
from NLCHI all patients who met the study’s inclusion criteria.   
The sample size calculations were performed using the JavaStat-Binomial Proportion 
Differences Tool developed by John Pezzullo. The calculator for proportion differences can be found 
at: http://www.statpages.org/proppowr.html 
3.5 Analysis:  
All analyses were performed using SPSS software. The initial analysis grouped patients based 
on their exposure status, however, not all of those in the exposed group remained on a statin for the 
entire five years of follow up, and we wondered whether the decreased adherence would change the 
primary outcomes. By including people in the exposed group who had actually stopped taking their 
statin medication, we were effectively diluting the potential beneficial effect of the statin therapy on 
our outcomes. We therefore completed a second analysis where the exposed group consisted only of 
those who were on statins at baseline and who had taken the statin for 80% or more of the time (1460 
days) during the five year follow up period.  
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3.5.1 Statistical Analysis  	
We performed univariate analysis on the demographic data for both the exposed and non-
exposed cohorts in order to describe the basic features of the data, and to determine whether the groups 
were similar or different at baseline.   
A chi-square test was used to compare the primary and secondary outcomes (CAD/ischemic 
heart disease, cerebrovascular disease, PVD, hospitalization for any reason, hospitalization for CVD, 
death from CVD) by the exposure group. We also used chi-square to compare the incidence of DM 
between the exposed and non-exposed cohort.  
The primary outcomes of CVD and all-cause mortality were then compared to other potential 
CVD risk factors/predictors at baseline (age, sex, diagnosis of HTN, smoking status, BMI, LDL-C, 
HDL-C, sBP, dBP, TC, TT). Chi-square with the Pearson continuity correction was used to compare 
the outcomes of dichotomous data and t-test for equality of means was used to assess the difference 
between group means of continuous variables.   
Logistic regression was used to estimate the relationship between the predictor variable (statin 
use) and primary outcomes (CVD and all-cause mortality), when only controlling for covariates of age 
and sex. A second regression was done using the covariates that were significant on univariate analysis. 
Only those risk factors that were found to be significant predictors of the outcomes on logistic 
regression are presented in tables 6(b) &7(b). For the logistic regression, all of the missing data was 
coded as ‘unknown’ allowing us to maintain a large sample size for the analysis.  
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Chapter 4  
Results 
 
Of the 9,134 patient records, we had full data for all patients on age, sex, statin exposure, 
diagnosis of HTN, individual CVD outcomes, hospitalization and death. We had incomplete data on 
statin dosage, smoking status (approximately 50% of participants), BMI (approximately 16%), LDL-C 
(approximately 11%), and BP (approximately 41%). The data was incomplete as it was unavailable for 
a large proportion of our patients. As such, our analyses were limited by a small sample size of patients 
who had records for all variables known to increase the risk of CVD.  
4.1 Baseline Data  
The exposed and non-exposed groups are compared in Table 3. The exposed group has a higher 
proportion of people with risk factors for CVD: they are more likely to be male, are older, are more 
likely to have a diagnosis of HTN, have a higher BMI and TT, a lower HDL-C, and have higher sBP. 
This can be expected given that they were started on a statin drug by their physicians, suggesting that 
the physicians perceived them as being at higher risk. The exposed group have a better lipid profile 
with lower total and LDL-C but this is not unexpected given they are taking a statin drug which lowers 
cholesterol.  
 
 
 		
			
		 31	
Table	3	Cohorts at Baseline (December 31, 2008). Comparison of Exposed vs. Non-Exposed 
Groups	
 Total N=9134 
Exposed 
N=720 
Non-
Exposed 
N=8414 
P value exposed vs non-
exposed 
Sex 
(n/%) 
Female 5421 
(59.3%) 
374  
(51.9%) 
5047 
(60.0%) 0.001Ӽ Male 3713 
(40.7%) 
346 
(48.1%) 
3367 
(40.0%) 
Age 
Mean (SD) 58.3 (5.7) 60.2 (5.6) 58.1 (5.7) 0.001
Ʈ 
Existing HTN Diagnosis 1171 (12.8%) 
298  
(41.4%) 
873  
(10.4%) 0.001
 Ӽ 
Smoking Status 
 
Current/Ever 1906 (20.9%) 
180 
(3.9%) 
1726 
(37.4%) 
0.309 Ӽ 
Never 2705 (29.6%) 
232 
(5.0%) 
2473 
(53.6%) 
BMI† 
Mean (SD) 
 
28.3 (5.5) 
N=1486 
29.2 (4.4) 
n =158 
28.2 (5.6) 
n=1328 0.035
 Ʈ 
TC†† 
Mean (SD) 
5.6 (1.06) 
 N=1019 
5.2 (1.08) 
n=204 
5.7 (1.04) 
n=815 0.001
 Ʈ 
LDL cholesterol 
Mean (SD) 
3.5 (0.90) 
N=964 
3.1 (0.97) 
n=199 
3.6 (0.86) 
n=765 0.001
 Ʈ 
HDL Cholesterol 
Mean (SD) 
1.3 (0.39) 
N=958 
1.2 (0.35) 
n=197 
1.4 (0.39) 
n=761 0.001
 Ʈ 
HDL/Total Ratio 
Mean (SD) 
4.5 (1.3) 
N=951 
4.5 (1.2) 
n=196 
4.5 (1.3) 
n=756 0.70
 Ʈ 
TT 
Mean (SD) 
41.6 
(0.97) 
N=869 
1.8 (0.96) 
n=187 
1.5 (0.97) 
n=682 0.003
 Ʈ 
Systolic BP††† 
Mean (SD) 
128.9 
(14.6) 
N=3140 
131.4.7 
(13.7) 
n=558 
128.4 
(14.8) 
n=2582 
0.001 Ʈ 
Diastolic BP 
Mean (SD) 
78.4 (8.5) 
N=3141 
78.8 (8.2) 
n=558 
78.2 (8.6) 
n=2583 0.12
 Ʈ 
Ӽ P value for Chi Square  
Ʈ P value for T test 
† BMI data was only available on 16.3% of patients  
†† Lipid data was only available on 10.6% of patients  
††† BP data was only available on 34.4% of patients  
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4.2 Univariate Analysis of the Effect of Statins on Primary and Secondary Outcomes  
The results of the univariate analysis are detailed in tables 4a and 4b. The exposed group, being 
on a statin at baseline was 1.36 times more likely to develop the composite outcome of CVD during the 
five year follow up period. There was no significant difference in all-cause mortality between the two 
groups. The results for the secondary outcomes, which consisted mainly of the individual components 
of the composite outcome, are detailed in table 4b. Those in the exposed group were either at increased 
risk of the outcome (CAD and hospitalization for any reason) or there was no difference between the 
groups. 
4.3 Baseline Risk Factors and the Primary Outcomes 
  Given the unexpected outcomes for the main predictor variable of exposed vs. unexposed, we 
assessed how the known CVD risk factors in our data were associated with our primary outcomes. If 
there was also a reversal of expected results, we would have been concerned that our data was coded 
incorrectly. For example, if known risk factors for CVD (e.g. high sBP, smoking, increased age, HTN) 
were negatively associated with CVD, we would be concerned that there was an error with the data. 
However, as shown in tables 5a and 5b, the risk factors were associated in the expected direction: 
males, older people, those with higher BMIs, smokers, those with lower HDL-C, and those with higher 
sBP were all more likely to have the composite outcome of CVD. Similarly, males, older people, and 
smokers were more likely to experience all-cause mortality. These results provide validity for the data 
and suggest our findings related to statin exposure are not systematically biased in some way.  
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Table	4	Table of Primary and Secondary Outcomes vs. Statin Exposure	
Table 4(a): Primary Outcomes  
 Exposure to Statin at 
Baseline OR; 95% CI; P value 
Interpretation 
 Yes No   
Composite 
Outcome: All CVD 
89 (12.4%) 791 (9.4%) 1.36 (1.08-1.72) 
0.012 
(Pearson Chi Square Continuity 
Correction) 
People in the exposed group (on a statin at baseline) 
were significantly more likely (1.36 times) to 
experience the composite outcome than those in the 
non-exposed group. 
All-Cause 
Mortality 
15 (2.1%) 264 (3.1%) 0.66 (0.39-1.11) 
0.143 
The outcome of all-cause mortality was not 
significantly different between the exposed and 
non-exposed groups 	
Table 4(b): Secondary Outcomes  
 Exposure to Statin at 
Baseline OR; 95% CI; P value 
Interpretation 
 Yes No   
Coronary Artery 
Disease/Ischemic 
Heart Disease  
53 (7.4%) 467 (5.6%) 1.35 (1.01-1.81) 
0.054  
(Pearson Chi Square Continuity 
Correction) 
People in the exposed group were significantly 
more likely (1.35 times) to develop CAD compared 
to the non-exposed group.   
Cerebrovascular 
Disease 
13 (1.8%) 118 (1.4%) 1.29 (0.73-2.30) 
0.478 
(Pearson Chi Square Continuity 
Correction) 
The outcome of cerebrovascular disease was not 
statistically significantly different between the 
exposed and non-exposed groups  
Peripheral 
Vascular Disease  
15 (2.1%) 113 (1.3%) 1.56 (0.91-2.69) 
0.145 
(Pearson Chi Square Continuity 
Correction) 
The outcome of PVD was not statistically 
significantly different between the exposed and 
non-exposed groups 
Hospitalization 
Any Reason 
416 (57.8%) 4424(52.8%) 1.23 (1.06-1.44) 
0.008 
(Pearson Chi Square Continuity 
Correction) 
People in the exposed group were significantly 
more likely (1.23 times) to be hospitalized for any 
reason compared to those in the non-exposed group 
Hospitalization for 
CVD Reason 
30 (4.2%) 297 (3.5%) 1.19 (0.81-1.74) 
0.436 
The outcome of hospitalization for CVD was not 
statistically significantly different between the 
exposed and non-exposed groups 
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(Pearson Chi Square Continuity 
Correction) 
CVD Mortality 4 (0.6%) 34 (0.4%) 1.38 (0.49-3.89) 
0.539  
(Fisher’s Exact test) 
The outcome of CVD mortality was not 
significantly different between the exposed and 
non-exposed groups 		
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Table 5 Effect of Baseline Risk Factors on Primary Outcomes 
Table 5(a): CVD (composite outcome)   
 Composite Outcome (Any CVD) 
OR; 95% CI; P value 
(Mean Diff (SD) for 
continuous variables 
Interpretation 
 Yes No 1.93 (1.68-2.22) 
0.001 
(Pearson Chi Square Continuity 
Correction) 
 
Males were significantly more likely (1.93 
times) to have an outcome of CVD compared 
to females Sex 
Male 487 (13.1%) 3226 
Female 393 (7.2%) 5028 
Mean Age (SD) 60.32 (5.9) 58.04 (5.6) Mean Diff 2.32 (1.93-2.93) 0.001 (t-test for equality of means) 
Older people were significantly more likely to 
have an outcome of CVD compared to 
younger people  
 
HTN 
diagnosis at 
baseline 
Yes 117 (10.0%) 1054 
1.05 (0.85-1.29) 
0.696  
(Pearson Chi Square Continuity 
Correction) 
People with a diagnosis of HTN at baseline 
were no more likely to have an outcome of 
CVD compared to those without HTN at 
baseline  No 763 (9.6%) 7200 
Currently or 
Ever Smoked  
Yes  272 
(14.3%) 
1634 2.03 (1.68-2.46) 
0.001 
(Pearson Chi Square Continuity 
Correction) 
Current or ever smokers were significantly 
more likely (2.03 times) to have an outcome 
of CVD compared to those who had never 
smoked  
No 205 (7.6%) 2500 
  
 
LDL-C Mean (SD) 
3.48 (0.98) 
N=96 
3.53 (0.90) 
N=868 
Mean Diff: -0.05 (-0.24-0.14) 
0.624 
(t-test for equality of means)  
People with higher LDL-C were no more  
likely to have an outcome of CVD compared 
to those with lower LDL-C 
HDL-C Mean (SD) 1.24 (0.33) 
N=95 
1.33 (0.40) 
N=863 
Mean Diff: -0.095 (-0.18- (-0.01)) 
0.025 
(t-test for equality of means) 
People with a low HDL-C were significantly 
more likely to have an outcome of CVD 
compared to those with a higher HDL-C 
BMI Mean (SD) 29.7 (6.6) 
N=129 
28.2 (5.4) 
N=1357 
Mean Diff: 1.55 (0.56-2.54) 
0.010  
(t-test for equality of means)  
People with a higher BMI were significantly 
more likely to have an outcome of CVD 
compared to those with a lower BMI 
sBP Mean (SD) 131.5 (15.1) 
N=262 
128.7 (14.6) 
N=2878 
Mean Diff: 2.85 (1.00-4.71) 
0.003  
(t-test for equality of means)  
People with a higher sBP were significantly 
more likely to have an outcome of CVD 
compared to those with a lower sBP 
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dBP Mean (SD) 78.5 (8.3) 
N=263 
78.4 (8.5) 
N=2878 
Mean Diff: 0.10 (-0.97-1.18) 
0.854 
(t-test for equality of means)  
People with a higher dBP were no more likely 
to have an outcome of CVD compared to 
those with a lower dBP  
TC (Mean) 5.41 (1.06) 
N=99 
5.58 (1.07) 
N=920 
Mean Diff: -0.17 (-0.39-0.05) 
0.136 
(t-test for equality of means) 
People with a higher TC were no more likely 
to have an outcome of CVD compared to 
those with lower TC 
TT (Mean)  1.59 (0.79) 
N=85 
1.58 (0.99) 
N=784 
Mean Diff: 0.00 (-0.21-0.22) 
0.959 
(t-test for equality of means) 
People with a higher TT were no more likely 
to have an outcome of CVD compared to 
those with lower TT 
 
Table 5(b): All –cause mortality    
 All-cause mortality   
OR; 95% CI; P value 
(Mean Diff (SD) for 
continuous variables 
Interpretation 
 Yes No 1.53 (1.21-1.94) 
0.001 
(Pearson Chi Square Continuity 
Correction) 
 
Males were significantly more likely (1.53 
times) to die compared to females  Sex 
Male 142 (3.8%) 3571  
Female 137 (2.3%) 5284  
    Mean Age (SD) 61.02 (5.9) 58.18 (5.7) 
Mean Diff: 2.84 (2.14-3.55) 
0.001 
(t-test for equality of means) 
Older people were significantly more likely to 
die compared to younger people 
 
HTN 
diagnosis at 
baseline 
Yes 37(3.2%)  1134 1.04 (0.73-1.48) 
0.984 
(Pearson Chi Square Continuity 
Correction) 
People with a diagnosis of HTN at baseline 
were no more likely to die compared to 
people without HTN  No 242(3%) 7721 
Currently or 
Ever Smoked  
Yes  72 (3.8% 1834 2.49 (1.69-3.66) 
0.001 
(Pearson Chi Square Continuity 
Correction) 
People who currently or previously smoked 
were significantly more likely (2.49 times) to 
die compared to those who had never smoked 
No 42 (2.2%) 2663 
LDL-C Mean (SD) 3.56 (1.1) 
N=17 
3.52 (0.90) 
N=947 
Mean Diff: 0.04 (-0.50-0.58) 
0.882 
(t-test for equality of means) 
People with higher LDL-C were no more  
likely to die compared to those with lower 
LDL-C 
HDL-C Mean (SD) 1.24 (0.33) 
N=17 
1.33 (0.39) 
N=941 
Mean Diff: -0.085 (-0.26-0.09) 
0.308 
(t-test for equality of means) 
People with lower HDL-C were no more  
likely to die compared to those with lower 
HDL-C 
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BMI Mean (SD) 27.4 (6.3) 
N=30 
28.4 (5.5) 
N=1456 
Mean Diff: -0.94 (-3.30-1.42) 
0.423 
(t-test for equality of means) 
People with higher BMI were no more  
likely to die compared to those with lower 
BMI 
sBP Mean (SD) 129.5 (17.2) 
N=81 
128.9 (14.6) 
N=3059 
 Mean Diff: 0.63 (-3.20-4.45) 
0.746 
(t-test for equality of means) 
People with a higher sBP were no more likely 
to die compared to those with a lower sBP 
dBP Mean (SD) 77.8 (8.6) 
N=81 
78.4 (8.5) 
N=3060 
Mean Diff: -0.60 (-2.52-1.33)  
0.539 
(t-test for equality of means) 
People with a higher dBP were no more likely 
to die compared to those with a lower dBP 
TC (Mean) 5.5 (1.4) 
N=19 
5.7 (1.1) 
N=1000 
Mean Diff: -0.02 (-0.69-0.66) 
0.950 
(t-test for equality of means) 
People with a higher TC were no more likely 
to die compared to those with lower TC 
TT (Mean)  1.7 (0.86) 
N=17 
1.6 (0.98) 
N=852 
Mean Diff: 0.13 (-0.32-0.57) 
0.553 
(t-test for equality of means) 
People with a higher TT were no more likely 
to die compared to those with lower TT 
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4.4 Logistic Regression with the Primary Outcome of CVD as the Dependent 
Variable 
We first used logistic regression to assess the relationship between statin exposure at 
baseline and the primary outcomes of CVD and all-cause mortality when controlling for 
covariates of age and sex (Table 6a). Because the exposed group was older and had a greater 
proportion of males, both of which increase the risk of CVD, we postulated that the increased 
likelihood of CVD in the group taking statins might be due to the bias associated with these 
higher risk people. This was in fact the case and as shown in table 6a the increased risk of CVD 
in those people taking statins was no longer statistically significant when age and sex were 
controlled for: (OR 1.13; 95% CI 0.89-1.43; P=0.304). Age and sex remained significant 
predictors of CVD. 
We also used logistic regression and included as covariates age and sex plus the other 
predictors of CVD (Table 6b) that were significant under univariate analysis (HDL-C, BMI, sBP, 
and smoking status). Only the risk factors that were significant after doing the logistic regression 
were presented in table 6b (age, sex, BMI, smoker). Being on a statin at baseline still did not 
significantly predict our CVD composite outcome in either direction.  
4.5 Logistic Regression with the Primary Outcome of All-cause Mortality as the 
Dependent Variable 
We used a similar process for logistic regression using all-cause mortality as the 
dependent variable. When controlling for just age and sex (Table 7a) we see that statin use 
significantly predicts all-cause mortality in the negative direction, i.e. being on a statin was 
associated with decreased rates of all-cause mortality. When we added smoking status to the 
covariate list, the results remained the same. 
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Table 6(a) Logistic Regression Estimating the Relationship Between Statin Exposure at 
Baseline and the Primary Outcome of CVD when Controlling for Covariates of Age and 
Sex (N=9134). 
Variables Beta Standard 
Error 
P value Odds 
Ratio 
95%CI 
Lower           Upper 
Statin Exposure at 
Baseline 
.125 .121 .304 1.133 .893 1.437 
Sex .668 .072 .000 1.951 1.694 2.247 
Age .070 .006 .000 1.073 1.060 1.086 
Constant -6.726 .379 .000 .001   
 
 
Table 6(b) Logistic Regression Estimating the Relationship Between Statin Exposure at 
Baseline and the Primary Outcome of CVD when Controlling for Covariates that were 
Significant on Univariate Analyses (age, sex, HDL, BMI, sBP, smoking status) (N=9134). 
Variables Beta Standard 
Error 
P value OR 95% CI 
Lower            Upper 
Statin Exposure at 
Baseline 
0.107 0.122 0.382 1.113 0.876 1.414 
Sex 0.643 0.072 0.001 1.903 1.651 2.193 
Age 0.072 0.006 0.001 1.075 1.062 1.088 
BMI ≥30 -0.431 0.194 0.026 0.650 0.444 0.951 
Current, Ever smoker -0.691 0.099 0.001 0.501 0.413 0.609 
Constant  -6.789 0.381 0.001 0.001   
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Table 7(a) Logistic Regression Estimating the Relationship Between Statin Exposure at 
Baseline and the Primary Outcome of All-Cause Mortality when Controlling for 
Covariates of Age and Sex (N= 9134). 
Variables Beta Standard 
Error 
P value OR 95% CI 
Lower            Upper 
Statin Exposure at 
Baseline 
-.626 .270 .020 .535 .315 .908 
Sex .446 .122 .000 1.561 1.229 1.984 
Age .087 .011 .000 1.091 1.069 1.114 
Constant -8.829 .652 .000 .000   
 
 
Table 7(b) Logistic Regression Estimating the Relationship Between Statin Exposure at 
Baseline and the Primary Outcome of All-Cause Mortality when Controlling for Baseline 
Covariates that were Significant on Univariate Analyses (age, sex, and smoking status) 
(N=9134). 
Variables Beta 
 
Standard 
Error 
P value OR 95% CI 
Lower            Upper  
Statin Exposure at 
Baseline 
-0.609 0.270 0.026 0.547 0.322 0.930 
Sex 0.424 0.123 0.001 1.528 1.201 1.943 
Age 0.087 0.011 0.001 1.091 1.069 1.114 
Current, Ever smoker -0.910 0.198 0.001 0.403 0.273 0.593 
Constant  -8.892 0.651 0.001 0.001   
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4.6 Logistic Regression Using Only Medication Compliant Individuals in the 
Exposed Group 	 We next assessed whether medication compliance (i.e. how compliant patients were in 
taking their medication) had an effect on our outcomes. When only using those exposed 
individuals who had taken statins for ≥80% of the time during the follow up period, the number 
of patients in the exposed group decreased from 720 to 633. Thus, 87.9% of our exposed 
population took their medication for at least 1460 days of the five year follow up period. Results 
demonstrate that statin exposure is still not a significant predictor of CVD (Table 8a), however, it 
remains a significant predictor of all-cause mortality (Table 8b).  
4.7 Incidence of Diabetes in the Exposed vs. Non-exposed Cohort   
 The percentage of new cases of DM in the exposed population was 10.3% compared to 
7.4% in the non-exposed. People in the exposed cohort were 1.42 times more likely to develop 
DM at follow up compared to those in the non-exposed. After accounting for medication 
compliance, (Table 9b) people in the exposed group were still significantly more likely (1.49 
times) to develop DM at follow up.  
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Table 8(a) Logistic Regression Estimating the Relationship Between Statin Exposure 
(based on ≥80% compliance) and the Primary Outcome of CVD when Controlling for 
Covariates that were Significant on Univariate Analyses (N=9047).  
Variables Beta 
 
Standard 
Error 
P value OR 95% CI 
Lower            Upper  
Statin Exposure at 
Baseline 
0.141 0.128 0.271 1.151 0.896 1.479 
Sex 0.644 0.073 0.001 1.904 1.651 2.196 
Age 0.072 0.006 0.001 1.075 1.061 1.088 
BMI ≥30 -0.443 0.195 0.023 0.642 0.438 0.941 
Current, Ever smoker -0.688 0.100 0.001 0.503 0.413 0.611 
Constant  -6.778 0.383 0.001 0.001   
 
 
Table 8(b) Logistic Regression Estimating the Relationship Between Statin Exposure 
(based on ≥80% compliance) and the Primary Outcome of All-Cause Mortality when 
Controlling for Covariates that were Significant on Univariate Analyses (N=9047).  
Variables Beta 
 
Standard 
Error 
P value OR 95% CI 
Lower            Upper  
Statin Exposure at 
Baseline 
-1.814 0.507 0.001 0.163 0.060 0.440 
Sex 0.410 0.125 0.001 1.507 1.179 1.926 
Age 0.086 0.011 0.001 1.090 1.067 1.113 
Current, Ever smoker -0.945 0.204 0.001 0.389 0.261 0.579 
Constant  -8.841 0.662 0.001 0.001   
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Table 9(a) Statin Exposure vs. Diagnosis of Diabetes at Follow up (N=9134). 
 
 
Statin Exposure at 
Baseline 
OR; 95% CI; P 
value 
Interpretation 
 Yes No   
Diabetes Dx at 
follow up  
139 
(10.3%) 
1210  
1.42; (1.17-1.73) 
0.001 
People in the exposed group 
were significantly more likely 
(1.42 times) to develop diabetes 
at follow up compared to the 
non-exposed group 
No Diabetes Dx 
at follow up 
581 
(7.4%) 
7204 
 
Table 9(b) Statin Exposure vs. Diagnosis of Diabetes at Follow up in the Medication 
Compliant Population (N=9047). 
 
 
Statin Exposure at 
Baseline 
OR; 95% CI; P 
value 
Interpretation 
 Yes No   
Diabetes Dx at 
follow up  
127 (9.5%) 1210 1.49; (1.22-1.83) 
0.001 
People in the exposed group 
were significantly more likely 
(1.49 times) to develop DM at 
follow up compared to the 
non-exposed group 
No Diabetes Dx 
at follow up 
506 (6.6%) 7204 
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Chapter 5 
Discussion 
	
5.1 Summary of Study 
The current research study investigated the use of statin drug therapy among primary 
prevention patients using EMR data provided by family physicians in NL. The research 
questions asked whether statin drug therapy decreased the occurrence of CVD and all-cause 
mortality and whether this effect changed when we accounted for known CVD risk factors of 
age, sex, BMI, LDL-C, HDL-C, HTN, TC, TT, smoking, and BP. Additionally, we wished to 
investigate the effects of medication compliance on our primary outcomes, and whether statin 
use increased the adverse effect of DM in our study population.  
In accordance with previous research, our alternative hypothesis (Ha) stated that the statin 
exposure group would experience fewer outcomes of CVD and all-cause mortality compared to 
the control group. Using the study conducted by Shalev et al., (2012) as a guideline, we 
hypothesized that the exposed group would demonstrate a 25-30% relative risk reduction in 
CVD compared to the non-exposed group. Lastly, we expected a significant increase in the 
incidence of DM type 2 in our statin group.    
The data was analyzed first according to the initial assessment of baseline exposure to statins 
and subsequently analyzed using only a medication compliant population. The latter allowed us 
to attribute the outcomes only to those people in the exposed group who remained on a statin for 
at least 80% of the five year follow up period. In contrast to our hypothesis, the univariate 
analysis revealed that the statin exposed group had higher rates of CVD (composite outcome), 
CAD and hospitalization compared to the non-exposed group. All other secondary outcomes 
were not significant. This positive association between statin exposure and CVD was no longer 
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significant when we performed a logistic regression and controlled for significant risk factors of 
age, sex, HDL-C, BMI, sBP and smoking status. In support of our hypothesis, our univariate 
analysis revealed that statin use was associated with a decrease in all-cause mortality at the end 
of follow up. This association remained significant even after controlling for CVD risk factors. 
Additionally, in accordance with our Ha our exposed group was found to have statistically 
significant higher rates of DM compared to the control group.  
5.2 Interpretation of Findings   
5.2.1 Primary Outcomes  
While the univariate analysis suggested that statin drugs actually increased the likelihood of 
developing CVD when used for primary prevention, logistic regression revealed that this was 
due to the difference in CVD risk between the groups. In the end, statin usage had no effect on 
CVD outcomes. 
As a better assessment of baseline risk, it will be important to calculate the FRS for each 
patient, and stratify patients based on their perceived 10-year CVD risk (≤10%, 10-19%, ≥20%). 
Due to missing data we were unable to calculate Framingham scores. While risk stratification 
will be important for future research, it is possible that it would not have made a difference in 
our study. Results published by the CTT Collaborators (2012) revealed that statins significantly 
reduced the risk of major vascular events and all-cause mortality “irrespective of age, sex, 
baseline LDL-C or previous vascular disease”4. Interestingly, the proportional reduction in 
vascular events was similar across all risk groups and was “at least as big in the two lowest risk 
categories as in the higher risk categories” 4. It may be the case that even though we failed to 
stratify our cohorts based on risk, this would not have mattered.   
The primary outcome of all-cause mortality, controlling for other risk factors under logistic 
regression, was found to be significantly decreased in our statin exposed group. Note there was 
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no significant difference in CVD specific related mortality between the two groups. As 
previously discussed, statins have been shown to have non lipid related effects. They possess 
“anti-inflammatory properties, inhibit vascular smooth muscle cell proliferation as well as 
platelet function, and improve vascular endothelial function”23. It has also been suggested that 
statins slightly increase the levels of HDL-C, or ‘good cholesterol’24. This could explain the 
protective factor of statins in terms of all-cause mortality. A second possibility is the fact that 
due to other comorbidities and risk factors, these patients were more likely to be prescribed other 
risk reducing medications (e.g. beta blockers, ACE-I, aspirin) in addition to lifestyle changes to 
reduce their chance of disease.  
Table 5 examined whether risk factors of CVD were significantly associated with the primary 
outcomes of CVD and all-cause mortality. Table 5a suggested that sex (male), increased age, 
history of smoking, decreased HDL-C, increased BMI and increased sBP were significantly 
associated with the composite outcomes of CVD. Likewise, sex (male), increased age and history 
of smoking were significantly associated with all-cause mortality (Table 5b). These findings are 
in accordance with known risk factors for CVD morbidity and mortality, and as previously 
discussed provide validity for the data by suggesting that our findings related to statin exposure 
are not systematically biased in some way. 
5.2.2 Medication Compliance  
According to previous research, medication adherence rates among statin users can be as low 
as 25% after five years36, with “fewer than 50% of patients take 80% or more of their prescribed 
statin dosages”6. Other studies have reported that patients who were more compliant with their 
medication were less likely to develop CVD37. It could therefore be hypothesized that controlling 
for medication compliance in our study population would result in more profound decreases in 
the rates of our primary outcomes (CVD and all-cause mortality).  
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Of the 720 patients initially exposed to statin therapy at baseline, 633 (87.9%) remained on a 
statin for ≥80% of the study period. The value of 80% was chosen as a target in order to remain 
consistent with current literature6,37. This large proportion of 87.9% compliance was unexpected. 
When we repeated the logistic regression analysis using only those exposed patients who had 
been compliant, there was no difference in the results.  
Although we do not know the reason why 12.1% of patients were not adherent or 
discontinued with statin medication by the end of follow up, likely possibilities are related to 
adverse effects, inability to adhere to daily medication, medication cost, or death.  
5.2.3 Incidence of Diabetes  
By the end of follow up, 14.8% of patients in the study had developed DM. In concordance 
with our hypothesis, a significantly higher number of these patients were using a statin. 
However, the modest increase of 2.9% was not as high as what was reported by the Diabetes 
safety task force31 and Shah and colleagues32. Recall that the CPCSSN case definition for 
diabetes was cited as 100% sensitivity, 99% specificity, and for NL only data: 95.6% sensitivity, 
97.1 specificity48. It is possible however, that the algorithm may not identify DM if the care was 
provided somewhere else (i.e. not by the primary care physician) or the data was not entered by 
the provider in the EMR. There is also the possibility of a time delay; a patient may be diagnosed 
with DM months before the algorithm detects the disease due to the requirement of multiple data 
points.  
5.2.4 Summary of Results  
In summary, our analysis suggests that statin drugs, when used for primary prevention, do 
not reduce the likelihood of developing CVD but do result in a decrease in all-cause mortality 
when other significant risk factors were controlled for.  
		 48	
5.3 Limitations  
This study’s data was obtained by linking several databases and as a result there were various 
limitations with respect to data linkage and secondary data use in general. A limitation to 
secondary data use is incomplete information and poor documentation resulting in reduced 
sample size, especially when attempting regression analysis. The validity of the CPCSSN 
database relies on the accuracy of the physician’s EMR, and how exact the physicians were at 
recording their patients past and current medical history. Family history, weight, height, and 
other lab and clinical data are often not reported if the patient is healthy. Smoking status is 
inconsistently recorded in EMRs. For example: if the smoking status column is blank, it could 
mean that the patient is either a non-smoker or the physician failed to document it. This 
ambiguous recording might affect the accuracy of our data, and “assuming that the patient does 
not have the condition overestimates the accuracy of the CPCSSN diagnostic algorithm”48. 
While the use of an ‘unknown’ categorical variable is a legitimate means of dealing with missing 
data when performing regression analysis, it is possible that it can lead to an overestimation of 
the effect of the intervention or exposure as it maintains the power by maintaining the sample 
size. 
As previously discussed, data for risk factors were poorly recorded in our patient population 
and as a result we were unable to calculate a patient’s FRS and stratify them accordingly. Even if 
this was possible, a lack of family history would have led to a misclassification bias with high 
risk patient’s potentially being classified as low-moderate based on their risk factors. 
Additionally, we did not assess whether patients were taking other medications in addition to 
statins (e.g. beta blockers, ACE-I) which could further reduce their risk of CVD. For future 
studies, matching could be employed when choosing cohorts to ensure that they are statistically 
similar at baseline. Matching was not used for this study as we had intended to use the FRS to 
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stratify patients. Lastly, we had no information regarding medication dosage. It is very likely that 
the intensity of statin treatment increased for patients over the study period. However, if this 
were the case we should have seen a more significant decrease in outcomes of CVD.  
For our study we assessed medication adherence as 80%. We chose to define compliance as 
evidence that the statin was prescribed for 80% of the follow-up time. It is important to 
distinguish between EMR prescription data and real world patient compliance. Our study 
assumed that patients were adherent to their medication if they were being prescribed a statin 
according to their EMR chart. However, this differs from “real” compliance as we do not know 
whether patients were actually filling their prescriptions and taking their medication daily. While 
it is possible to calculate adherence for RCT studies (e.g. subjective measurements by asking 
patients and family members, objective measurements by counting pills and examining 
pharmacy refill records, or biological measurements by detecting the presence of the drug in 
blood or urine51) it is difficult to measure adherence during a retrospective cohort study.  
Lastly, no discussion on the benefits of statin drugs would be complete without discussing 
the potential adverse effects in a real world population. Unfortunately, this study could not 
provide such information as the CPCSSN database rarely records adverse events. For those 
patients who stopped taking statins during the study period, it is possible that a proportion 
stopped due to adverse events, poor compliance, cost or death, but as previously mentioned we 
do not know for certain.  
A limitation to the CPCSSN database specifically is that it represented a population of 
patients who i) saw a primary care physician during the study period, and ii) whose primary care 
physician uses an EMR. To date, 50 physicians (approximately 10% of all NL primary care 
providers) and over 44,000 patient records are sent to CPCSSN; 38 physicians (76%) are located 
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in the urban settings of St. John’s and Corner Brook while 12 physicians (24%) are located in 
more rural communities across the province. The CPCSSN database may not be representative of 
the provincial and/or national population.   
5.4 Recommendations for Future Research 
Future research will require a larger data set with more complete data for each patient. 
This may be achieved by using the entire Canadian CPCSSN dataset, once it is able to perform 
linkage studies with each province. Currently only NL, Manitoba and Ontario have those 
capabilities. As of now, the CPCSSN database has 8 years worth of data, and physicians are 
continually learning how to better and more accurately record their patient data in EMRs.  
Using a matched cohort approach would also be useful in future studies. Matching for 
age and sex, for instance, would result in more similar groups.  
Future studies could examine length of time on a statin compared to outcomes of CVD. 
As previously mentioned, a study that also examines adverse effects of statins (besides DM) will 
be important for assessing efficacy and risk-benefit ratio in a real world setting.   
5.5 Conclusions  
The elements of this paper have real-world implications and suggest that the benefits of 
using statins in a primary prevention situation are not nearly as impressive as what randomized 
clinical trials suggest. This contradicts current wisdom, and has important implications for 
practitioners. 
After taking into account the various limitations, we still have to take seriously the 
findings of this study: The results cannot be ignored because several things speak to their 
validity: i) known risk factors in the data (e.g. age, sex, smoking) predict outcomes in the 
directions expected; ii) we were not able to calculate Framingham scores but we were able to 
control for a number of risk factors.  
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After performing all analyses, we can conclude that at best, statins had no effect on CVD 
outcomes but do decrease all-cause mortality.  
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